Pache.co Information Technologies

Funny animal videos! Compilation number 265. Only the best! Sit back and charge positively 😉 Funny animal videos (funny cats, dogs and other funny animals).

🙏🏻 Subscribe if you liked it, like it, leave comments and share with your friends.

🎬 Funny animals. Funny cats. Funny dogs. Funny animal videos. The most popular compilations from Happy Dog:
🥇 – https://youtu.be/0F9V8SixMbA
🥈 – https://youtu.be/mybNXbim9y4
🥉 – https://youtu.be/A3nzKV_2Qs8
🏅 – https://youtu.be/HlIu4WUToGU
🏅 – https://youtu.be/3lW_WlFksNU

🔔 Funny animals every week, turn on notifications on the channel so you don’t miss it!

⚠️ Our purpose, when making COMPILATIONS, is NOT to steal other people’s videos, but to share those in quality compilation with other people.

Funny animal videos / Funny cats / Funny dogs / Funny animals

⚠️ All copyrights belong to their legal owners! If you are the author of a fragment from the issue and its distribution infringes upon your copyright, please contact me. We will remove the clip, video or come to an agreement. Thank you! 🙏

Happy Dog is a channel containing collections of funny animal videos: funny cats, dogs, and many other funny animals. The channel was created to bring even more positive and joyful moments into your life! Funny cats (and other funny animals) will be released every week, subscribe, call your friends, and get a positive charge!

Funny animals (funny cats, parrots, dogs, horses, rodents, kittens, puppies, squirrels and many other funny animals). Only the best funny animal videos on the channel! The funniest animals are only here on Happy Dog!

______________________
funny animal videos,funny animal video,best animal videos,funny dog videos,funny cat videos,funny animals life,funny animal moments,funny animals 2023,funny animals,cute dogs and cats,funny videos,funniest dogs,funniest animals,dog videos,cat videos,funny video,animals life,cute funny cat,funny cats,funny dogs,cute videos,cute animals,cutest cats compilation,funny cat,funny dog,awesome animals,cute and funny dog,try not to laugh animals,puppies,dogs funny videos,kittens,funny animals cats and dogs,puppies and kittens,cats meowing,cats videos,dogs videos

#happydog

Max Verstappen heeft de laatste jaren flink aan populariteit gewonnen in de wereld. Met name tijdens het seizoen van 2021 wist hij de Formule 1 naar een hoger niveau te tillen, toen hij in een waanzinnige titelstrijd verwikkeld raakte met Lewis Hamilton. Verstappen hoopt echter niet dat deze strijd ooit verfilmd gaat worden. Ook een film over zijn leven ziet hij niet zitten.

Het vernieuwde Albert Park in Melbourne, het circuit waar we komend weekend gaan racen, lijkt maar liefst over vier DRS-zones te beschikken. Het wordt dus oppassen geblazen en er lijkt een hoop inhaalactie voor de boeg te liggen.

Montage door: Ronan Postulart

Volg ons op Spotify & Apple Podcast!
Spotify: https://open.spotify.com/show/0b8OzYI1FP76Jn9FXidfHL?si=nwbYxeOqShGVLwhA_YOYhA&dl_branch=1

Apple: https://podcasts.apple.com/us/podcast/gpfans-formule-1-nieuws-meer/id1586109422

Download ook de GPFans App!

Google Play | https://play.google.com/store/apps/details?id=com.fanreach.gpfans&gl=NL
AppStore | https://apps.apple.com/nl/app/gpfans/id1457679900

Bekijk ook onze social media kanalen:

Instagram: http://www.instagram.com/GPFansNL
Twitter: http://www.twitter.com/GPFansNL
Facebook: https://www.facebook.com/GPfanscom
TikTok: https://www.tiktok.com/@gpfansnl

Toolden is proud to offer free delivery on all orders to UK Mainland addresses for orders over the value of £50*

Your delivery method is chosen based on the value, weight and size of your total order. Orders will be shipped via Royal Mail, DPD or FedEx. Tracking information and delivery notifications are available directly from the courier.

We aim to dispatch all orders within 2-3 working days, however dispatch times can vary so each product has an estimated dispatch time for a more accurate guidance. We also offer direct delivery from some of our partnered manufacturers.

All UK mainland customers should expect to receive their orders no longer than 5 working days after their order is placed. If your goods have not been received after 6 working days, please email [email protected] and we will investigate further. Please allow extended time for European deliveries.

*Certain heavier/bulkier items might incur additional charges. The additional fee will be clearly stated at the checkout, before placing the order.

Mistakes happen, we’re all human! You may return most new, unopened items within 14 days of delivery for a full refund. We will cover the return shipping costs ONLY if the return is a result of our error and arrange for collection at a time convenient to yourself.

It is advisable to inspect the goods prior to signing for delivery. If you can see any damage whatsoever to the packaging please sign for the goods as damaged. If this is not possible please ensure you sign for the goods unexamined to allow us to take any claims up with our deliver partners if necessary.

All tools come with a manufacturers warranty. Most of our product pages have a link to the warranty procedure for that manufacturer and we encourage you to follow the instructions on these pages which will normally direct you to the manufacturers helpline. This is normally the fastest way of getting your warranty problem resolved.

If your order has been delivered damaged, is unwanted or you’ve ordered the wrong item:

If your item becomes faulty

Under guidelines set to us by manufacturers, we will advise you of the nearest repiar agent which is free of charge under your manufacturer’s warranty – please remember to register your item on the manufacturer’s website for the additional 2 years warranty. Please also see our Warranty section on the website for futher information. We do not accept returns of damaged or faulty items regardless of timescale. These will always need to be taken to an authorised repair agent or the manufacturer.

Please note that any items returned that have been altered, modified, defaced or undergone heavy usage may not be eligible for a full refund or replacement.

Please allow a maximum of four days to a week for your refund to process. It is often sooner than this however different banks process these with varying levels of efficiency.

If you need to return an item, please go log-in to your account and go to the ‘Completed’ section of your account page. This will show all completed orders and from here, you will be able to select the option for return and complete the form.

Please see the Royal Mail shipping restrictions to best select the option for return and complete the form.

Please click on this link if the web page does not reroute immediately …
Resource

Registration and Protocol

This review was registered at PROSPERO under the registration number CRD42022296596 (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=296596). A protocol was prepared in advance of conducting the study.

This work is part of a Master’s thesis of the Master’s Program in Clinical Research, Dresden International University, Dresden, Germany.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

TS received grants from the German Federal Ministry of Health and Kurt Goldstein Institut that were not related to this study. TS received royalties from AstraZeneca for consulting and from Dresden International University for serving as program director and lecturer of the Master’s Program in Clinical Research. TS is editorial board member at Neuropsychiatric Disease and Treatment. BI reports financial interest in NOVA discovery and Biomind that were not related to this study. BI serves as program director and lecturer for the Master’s Program in Clinical Research at Dresden International University. MSS, GAH, and AFA declare no potential conflicts of interest.

1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9

2. Bauer M, Monz BU, Montejo AL, et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry. 2008;23(1):66–73. doi:10.1016/j.eurpsy.2007.11.001

3. Chee K-Y, Tripathi A, Avasthi A, et al. International study on antidepressant prescription pattern at 40 major psychiatric institutions and hospitals in Asia: a 10-year comparison study. Asia Pac Psychiatry. 2015;7(4):366–374. doi:10.1111/appy.12176

4. Treviño LA, Ruble MW, Treviño K, Weinstein LM, Gresky DP. Antidepressant medication prescribing practices for treatment of major depressive disorder. Psychiatr Serv. 2017;68(2):199–202. doi:10.1176/appi.ps.201600087

5. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184–191. doi:10.1111/j.1600-0447.2009.01519.x

6. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman ATF. Recurrence of major depressive disorder and its predictors in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol Med. 2013;43(1):39–48. doi:10.1017/S0033291712002395

7. Mahlich J, Tsukazawa S, Wiegand F. Estimating prevalence and healthcare utilization for treatment-resistant depression in japan: a retrospective claims database study. Drugs Real World Outcomes. 2018;5(1):35–43. doi:10.1007/s40801-017-0126-5

8. Coppen A, Brooksbank BWL, Peet M. Tryptophan concentration in the cerebrospinal fluid of depressive patients. Lancet. 1972;299(7765):1393. doi:10.1016/S0140-6736(72

9. McClure DJ. The role of dopamine in depression. Can Psychiatr Assoc J. 1973;18(4):309012.

10. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509–522. doi:10.1176/ajp.122.5.509

11. Köhler CA, Freitas TH, Maes M, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017;135(5):373–387. doi:10.1111/acps.12698

12. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5166 patients and 5083 controls. Brain Behav Immun. 2020;87:901–909. doi:10.1016/j.bbi.2020.02.010

13. Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012;279(8):1375–1385. doi:10.1111/j.1742-4658.2012.08551.x

14. Arteaga-Henriquez G, Burger B, Weidinger E, et al. Activation and deactivation steps in the tryptophan breakdown pathway in major depressive disorder: a link to the monocyte inflammatory state of patients. Prog Neuropsychopharmacol Biol Psychiatry. 2021;107:110226. doi:10.1016/j.pnpbp.2020.110226

15. Grosse L, Carvalho LA, Birkenhager TK, et al. Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. Psychopharmacology. 2016;233:1679–1688. doi:10.1007/s00213-015-3943-9

16. Grosse L, Hoogenboezem T, Ambrée O, et al. Deficiencies of the T and natural killer cell system in major depressive disorder. T regulatory cell defects are associated with inflammatory monocyte activation. Brain Behav Immun. 2016;54:38–44. doi:10.1016/j.bbi.2015.12.003

17. Schiweck C, Valles-Colomer M, Arolt V, et al. Depression and suicidality: a link to premature T helper cell aging and increased Th17 cells. Brain Behav Immun. 2020;87:603–609. doi:10.1016/j.bbi.2020.02.005

18. Simon MS, Schiweck C, Arteaga-Henríquez G, et al. Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021;111:110391. doi:10.1016/j.pnpbp.2021.110391

19. Arteaga-Henríquez G, Simon MS, Burger B, et al. Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-moodinflame consortium. Front Psychiatry. 2019;10:458. doi:10.3389/fpsyt.2019.00458

20. Simon MS, Burger B, Weidinger E, et al. Efficacy of sertraline plus placebo or add-on celecoxib in major depressive disorder: macrophage migration inhibitory factor as a promising biomarker for remission after sertraline – results from a randomized controlled clinical trial. Front Psychiatry. 2021;12:615261. doi:10.3389/fpsyt.2021.615261

21. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 2015;25(10):1532–1543. doi:10.1016/j.euroneuro.2015.06.007

22. Freeman MP, Davis M, Sinha P, Wisner KL, Hibbeln JR, Gelenberg AJ. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord. 2008;110(1–2):142–148. doi:10.1016/j.jad.2007.12.228

23. Müller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–684. doi:10.1038/sj.mp.4001805

24. Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.

25. Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–9313. doi:10.3748/wjg.v22.i42.9300

26. Ershad M, Naji A, Vearrier D. N acetylcysteine. In: StatPearls. Treasure Island (FL): StatPearls Publishing;; 2022.

27. Pedre B, Barayeu U, Ezeriņa D, Dick TP. The mechanism of action of N-acetylcysteine (NAC): the emerging role of H2S and sulfane sulfur species. Pharmacol Ther. 2021;228:107916. doi:10.1016/j.pharmthera.2021.107916

28. Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337–352. doi:10.1111/bph.12139

29. Nazarian S, Akhondi H. Minocycline. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.

30. Krupa K, Fritz K, Parmar M. Omega-3 fatty acids. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.

31. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor-alpha antagonist infliximab in treatment resistant depression: role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41. doi:10.1001/2013.jamapsychiatry.4

32. Hasebe K, Gray L, Bortolasci C, et al. Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. Acta Neuropsychiatr. 2017;29(6):337–346. doi:10.1017/neu.2017.2

33. Musil R, Schwarz MJ, Riedel M, et al. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression — no influence of celecoxib treatment. J Affect Disord. 2011;134(1–3):217–225. doi:10.1016/j.jad.2011.05.047

34. Nettis MA, Lombardo G, Hastings C, et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology. 2021;46(5):939–948. doi:10.1038/s41386-020-00948-6

35. Husain MI, Chaudhry IB, Husain N, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol. 2017;31(9):1166–1175. doi:10.1177/0269881117724352

36. Su K-P, Huang S-Y, Chiu T-H, et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(4):644–651. doi:10.4088/jcp.v69n0418

37. Baune BT, Sampson E, Louise J, et al. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: a 6-week double-blind placebo controlled randomized trial. Eur Neuropsychopharmacol. 2021;53:34–46. doi:10.1016/j.euroneuro.2021.07.092

38. Mischoulon D, Nierenberg AA, Schettler PJ, et al. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry. 2015;76(1):54–61. doi:10.4088/JCP.14m08986

39. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71

40. Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019.

41. Kung J, Chiappelli F, Cajulis OO, et al. From systematic reviews to clinical recommendations for evidence-based health care: validation of Revised Assessment of Multiple Systematic Reviews (R-AMSTAR) for grading of clinical relevance. Open Dent J. 2010;4:84–91. doi:10.2174/1874210601004020084

42. PEROSH OSH Evidence Group. PEROSH – OSH evidence. Clearinghouse of systematic reviews. METHODS; 2014. Available from: https://perosh.eu/wp-content/uploads/2013/06/PEROSH-Clearinghouse-Methods_Last-update-June-2014.pdf. Accessed February 3, 2022.

43. Rosenblat JD, McIntyre RS. Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials. J Affect Disord. 2018;227:219–225. doi:10.1016/j.jad.2017.10.042

44. Zheng W, Zhu X-M, Zhang Q-E, et al. Adjunctive minocycline for major mental disorders: a systematic review. J Psychopharmacol. 2019;33(10):1215–1226. doi:10.1177/0269881119858286

45. Köhler-Forsberg O, Lydholm CN, Hjorthøj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139(5):404–419. doi:10.1111/acps.13016

46. Bai S, Guo W, Feng Y, et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020;91(1):21–32. doi:10.1136/jnnp-2019-320912

47. Hang X, Zhang Y, Li J, et al. Comparative efficacy and acceptability of anti-inflammatory agents on major depressive disorder: a network meta-analysis. Front Pharmacol. 2021;12:691200. doi:10.3389/fphar.2021.691200

48. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol. 2014;29(3):216–223. doi:10.1002/hup.2401

49. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:79–85. doi:10.1016/j.pnpbp.2013.09.006

50. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY. Corrigendum to “Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis” [Prog Neuropsychopharmacol Biol Psychiatry 48 (3 January 2014) 79–85]. Prog Neuropsychopharmacol Biol Psychiatry. 2016;66:136. doi:10.1016/j.pnpbp.2015.11.011

51. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381–1391. doi:10.1001/jamapsychiatry.2014.1611

52. Yuan Z, Chen Z, Xue M, Zhang J, Leng L. Application of antidepressants in depression: a systematic review and meta-analysis. J Clin Neurosci. 2020;80:169–181. doi:10.1016/j.jocn.2020.08.013

53. Martins JG, Bentsen H, Puri BK. Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol Psychiatry. 2012;17(12):1144–1167. doi:10.1038/mp.2012.25

54. Lin P-Y, Mischoulon D, Freeman MP, et al. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry. 2012;17(12):1161–1167. doi:10.1038/mp.2012.111

55. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One. 2014;9(5):e96905. doi:10.1371/journal.pone.0096905

56. Appleton KM, Sallis HM, Perry R, Ness AR, Churchill R. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev. 2015;11:CD004692. doi:10.1002/14651858.CD004692.pub4

57. Mocking RJT, Harmsen I, Assies J, Koeter MWJ, Ruhé HG, Schene AH. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 2016;6(3):e756. doi:10.1038/tp.2016.29

58. Sarris J, Murphy J, Mischoulon D, et al. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry. 2016;173(6):575–587. doi:10.1176/appi.ajp.2016.15091228

59. Wei-Hong L, Cheng-Gui Z, Peng-Fei G, Heng L, Jian-Fang Y. Omega-3 fatty acids as monotherapy in treating depression in pregnant women: a meta-analysis of randomized controlled trials. Iran J Pharm Res. 2017;16(4):1593–1599.

60. Schefft C, Kilarski LL, Bschor T, Köhler S. Efficacy of adding nutritional supplements in unipolar depression: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27(11):1090–1109. doi:10.1016/j.euroneuro.2017.07.004

61. Luo X-D, Feng J-S, Yang Z, et al. High-dose omega-3 polyunsaturated fatty acid supplementation might be more superior than low-dose for major depressive disorder in early therapy period: a network meta-analysis. BMC Psychiatry. 2020;20(1):248. doi:10.1186/s12888-020-02656-3

62. Jeremiah OJ, Cousins G, Boland F, Kirby BP, Ryan BK. Evaluation of the effect of insulin sensitivity-enhancing lifestyle- and dietary-related adjuncts on antidepressant treatment response: a systematic review and meta-analysis. Heliyon. 2020;6(9):e04845. doi:10.1016/j.heliyon.2020.e04845

63. Chambergo-Michilot D, Brañez-Condorena A, Falvy-Bockos I, Pacheco-Mendoza J, Benites-Zapata VA. Efficacy of omega-3 supplementation on sertraline continuous therapy to reduce depression or anxiety symptoms: a systematic review and meta-analysis. Psychiatry Res. 2021;296:113652. doi:10.1016/j.psychres.2020.113652

64. Lin P-Y, Su K-P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2020;81(5):19r13106. doi:10.4088/JCP.19r13106

65. Kraguljac NV, Montori VM, Pavuluri M, Chai HS, Wilson BS, Unal SS. Efficacy of omega-3 fatty acids in mood disorders – a systematic review and metaanalysis. Psychopharmacol Bull. 2009;42(3):39–54.

66. Marins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2009;28(5):525–542. doi:10.1080/07315724.2009.10719785

67. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72(12):1577–1584. doi:10.4088/JCP.10m06634

68. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry. 2012;17(12):127212–127282. doi:10.1038/mp.2011.100

69. Yang R-J, Han D, Qiao Z-X, Tian X, Qi D, Qiu X-H. Combined application of eicosapentaenoic acid and docosahexaenoic acid on depression in women: a meta-analysis of double-blind randomized controlled trials. Neuropsychiatr Dis Treat. 2015;11:2055–2061. doi:10.2147/NDT.S86581

70. Fernandez BS, Dean OM, Dodd S, Malhi GS, Berk M. N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry. 2016;77(4):e457–e466. doi:10.4088/JCP.15r09984

71. Hallahan B, Ryan T, Hibbeln JR, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry. 2016;209(3):192–201. doi:10.1192/bjp.bp.114.160242

72. Husain MI, Strawbridge R, Stokes PR, Young AH. Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis. J Psychopharmacol. 2017;31(9):1137–1148. doi:10.1177/0269881117725711

73. Bae J-H, Kim G. Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. Nutr Res. 2018;50:1–9. doi:10.1016/j.nutres.2017.10.013

74. Bai Z-G, Bo A, Wu S-J, Gai Q-Y, Chi I. Omega-3 polyunsaturated fatty acids and reduction of depressive symptoms in older adults: a systematic review and meta-analysis. J Affect Disord. 2018;241:241–248. doi:10.1016/j.jad.2018.07.057

75. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018;23(2):335–343. doi:10.1038/mp.2016.167

76. Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9(1):190. doi:10.1038/s41398-019-0515-5

77. Bavaresco DV, Uggioni MLR, Ferraz SD, et al. Efficacy of infliximab in treatment-resistant depression: a systematic review and meta-analysis. Pharmacol Biochem Behav. 2020;188:172838. doi:10.1016/j.pbb.2019.172838

78. Cai DB, Zheng W, Zhang QE, et al. Minocycline for depressive symptoms: a meta-analysis of randomized, double-blinded, placebo-controlled trials. Psychiatr Q. 2020;91(2):451–461. doi:10.1007/s11126-019-09707-3

79. Kishi T, Miyake N, Okuya M, Sakuma K, Iwata N. N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. Psychopharmacology. 2020;237(11):3481–3487. doi:10.1007/s00213-020-05629-2

80. Mocking RJT, Steijn K, Roos C, et al. Omega-3 fatty acid supplementation for perinatal depression: a meta-analysis. J Clin Psychiatry. 2020;81(5):19r13106. doi:10.4088/JCP.19r13106

81. Zhang MM, Zou Y, Li SM, et al. The efficacy and safety of omega-3 fatty acids on depressive symptoms in perinatal women: a meta-analysis of randomized placebo-controlled trials. Transl Psychiatry. 2020;10(1):193. doi:10.1038/s41398-020-00886-3

82. Deane KHO, Jimoh OF, Biswas P, et al. Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials. Br J Psychiatry. 2021;218(3):135–142. doi:10.1192/bjp.2019.234

83. Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry. 2010;68(2):140–147. doi:10.1016/j.biopsych.2010.03.018

84. Lin PY, Chang CH, Chong MF, Chen H, Su KP. Polyunsaturated fatty acids in perinatal depression: a systematic review and meta-analysis. Biol Psychiatry. 2017;82(8):560–569. doi:10.1016/j.biopsych.2017.02.1182

85. Yang Y, Kim Y, Je Y. Fish consumption and risk of depression: epidemiological evidence from prospective studies. Asia Pac Psychiatry. 2018;10(4):e12335. doi:10.1111/appy.12335

86. Tolkien K, Bradburn S, Murgatroyd C. An anti-inflammatory diet as a potential intervention for depressive disorders: a systematic review and meta-analysis. Clin Nutr. 2019;38(5):2045–2052. doi:10.1016/j.clnu.2018.11.007

87. Farooq S, Singh SP, Burke D, Naeem F, Ayub M. Pharmacological interventions for prevention of depression in high risk conditions: systematic review and meta-analysis. J Affect Disord. 2020;269:58–69. doi:10.1016/j.jad.2020.03.024

88. Asher GN, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of complementary and alternative medicine therapies for initial treatment of major depressive disorder: systematic review and meta-analysis. J Altern Complement Med. 2017;23(12):907–919. doi:10.1089/acm.2016.0261

89. Freeman MP, Mischoulon D, Tedeschini E, et al. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010;71(6):682–688. doi:10.4088/JCP.10r05976blu

90. Xu Y, Zeng L, Zou K, et al. Role of dietary factors in the prevention and treatment for depression: an umbrella review of meta-analyses of prospective studies. Transl Psychiatry. 2021;11(1):478. doi:10.1038/s41398-021-01590-6

91. Köhler O, Benros M, Nordentoft M, Mors O, Krogh J. Effect of anti-inflammatory treatment on depression and side effects: a systematic review and meta-analysis of randomized clinical trials. Pharmacoepidemiol Drug Saf. 2014;23(Suppl 1):252–253.

92. Köhler O, Benros M, Nordentoft M, Mors P, Krogh J. Effect of anti-inflammatory treatment on depression, depressive symptoms and side effects: a systematic review and meta-analysis of randomized clinical trials. Eur Psychiatry. 2015;30(Suppl 1):0342. doi:10.1016/S0924-9338(15)30268-6

93. Benros M. Immune-related risk factors for schizophrenia and depression in Danish epidemiological studies and meta-analysis of anti-inflammatory treatment for depression. Early Interv Psychiatry. 2016;10(Suppl 1):27.

94. Kim H-B, Kim J-S, Jung J-G. The association between aspirin use and depression: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2020;29(6):613–622. doi:10.1002/pds.5011

95. Suradom C, Suttajit S, Oon-Arom A, Maneeton B, Srisurapanont M. Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation for prevention and treatment of perinatal depression: a systematic review and meta-analysis of randomized-controlled trials. Nord J Psychiatry. 2021;75(4):239–246. doi:10.1080/08039488.2020.1843710

96. Reis DJ, Casteen EJ, Ilardi SS. The antidepressant impact of minocycline in rodents: a systematic review and meta-analysis. Sci Rep. 2019;9(1):261. doi:10.1038/s41598-018-36507-9

97. Zheng W, Zhang QE, Cai DB, et al. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2018;137(5):391–400. doi:10.1111/acps.12862

98. Emadi-Kouchak H, Mohammadinejad P, Asadollahi-Amin A, et al. Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial. Int Clin Psychopharmacol. 2016;31(1):20–26. doi:10.1097/YIC.0000000000000098

99. Dean OM, Kanchanatawan B, Ashton M, et al. Adjunctive minocycline treatment for major depressive disorder: a proof of concept trial. Aust N Z J Psychiatry. 2017;51(8):829–840. doi:10.1177/0004867417709357

100. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of ad- junctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607–611. doi:10.1002/da.20589

101. Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol B. 2011;21:S183–S184.

102. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012;141(2–3):308–314. doi:10.1016/j.jad.2012.03.033

103. Majd M, Hashemian F, Hosseini SM, Vahdat Shariatpanahi M, Sharifi A. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: a pilot study. Iran J Pharm Res. 2015;14(3):891–899.

104. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159(3):477–479. doi:10.1176/appi.ajp.159.3.477

105. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59(10):913–919. doi:10.1001/archpsyc.59.10.913

106. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. 2003;160(5):996–998. doi:10.1176/appi.ajp.160.5.996

107. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13(4):267–271. doi:10.1016/s0924-977x(03)00032-4

108. Silvers KM, Woolley CC, Hamilton FC, Watts PM, Watson RA. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids. 2005;72(3):211–218. doi:10.1016/j.plefa.2004.11.004

109. Grenyer BF, Crowe T, Meyer B, et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1393–1396. doi:10.1016/j.pnpbp.2007.06.004

110. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry. 2008;42(3):192–198. doi:10.1080/00048670701827275

111. Rees AM, Austin MP, Parker GB. Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry. 2008;42(3):199–205. doi:10.1080/00048670701827267

112. da Silva TM, Munhoz RP, Alvarez C, et al. Depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. 2008;111(2–3):351–359. doi:10.1016/j.jad.2008.03.008

113. Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA. 2009;302(15):1651–1657. doi:10.1001/jama.2009.1487

114. Lucas M, Asselin G, Merette C, Poulin MJ, Dodin S. Ethyleicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr. 2009;89:641–651. doi:10.3945/ajcn.2008.26749

115. Mischoulon D, Papakostas GI, Dording CM, et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry. 2009;70(12):1636–1644. doi:10.4088/JCP.08m04603

116. Bot M, Pouwer F, Assies J, et al. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J Affect Disord. 2010;126(1–2):282–286. doi:10.1016/j.jad.2010.04.008

117. Rondanelli M, Giacosa A, Opizzi A, et al. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr. 2010;29(1):55–64. doi:10.1080/07315724.2010.10719817

118. Gonzalez A, Mata S, Sanchez P, et al. Omega-3 fatty acids as adjunctive of antidepressant therapy and its effects on brain-derived neurotrophic factor in serum, monocytes and lymphocytes. Arch Venez Farmacol Ter. 2011;30(4):72–78.

119. Lespérance F, Frasure-Smith N, St-André E, Turecki G, Lespérance P, Wisniewski SR. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry. 2011;72(8):1054–1062. doi:10.4088/JCP.10m05966blu

120. Rondanelli M, Giacosa A, Opizzi A, et al. Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life. J Nutr Health Aging. 2011;15(1):37–44. doi:10.1007/s12603-011-0011-y

121. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol. 2012;32(1):61–64. doi:10.1097/JCP.0b013e31823f3b5f

122. Rizzo AM, Corsetto PA, Montorfano G, et al. Comparison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters. Nutr J. 2012;11:82. doi:10.1186/1475-2891-11-82

123. Mozaffari-Khosravi H, Yassini-Ardakani M, Karamati M, Shariati-Bafghi SE. Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2013;23(7):636–644. doi:10.1016/j.euroneuro.2012.08.003

124. Gharekhani A, Khatami MR, Dashti-Khavidaki S, et al. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol. 2014;70(6):655–665. doi:10.1007/s00228-014-1666-1

125. Park Y, Park YS, Kim SH, Oh DH, Park YC. Supplementation of n-3 polyunsaturated fatty acids for major depressive disorder: a randomized, double-blind, 12-week, placebo-controlled trial in Korea. Ann Nutr Metab. 2015;66(2–3):141–148. doi:10.1159/000377640

126. Rapaport MH, Nierenberg AA, Schettler PJ, et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 2016;21(1):71–79. doi:10.1038/mp.2015.22

127. Shinto L, Marracci G, Mohr DC, et al. Omega-3 fatty acids for depression in multiple sclerosis: a randomized pilot study. PLoS One. 2016;11(1):e0147195. doi:10.1371/journal.pone.0147195

128. Jahangard L, Sadeghi A, Ahmadpanah M, et al. Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders – results from a double-blind, randomized and placebo-controlled clinical trial. J Psychiatr Res. 2018;107:48–56. doi:10.1016/j.jpsychires.2018.09.016

129. Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. A randomized placebo-controlled trial of omega-3 and sertraline in depressed patients with or at risk for coronary heart disease. J Clin Psychiatry. 2019;80(4):19m12742. doi:10.4088/JCP.19m12742

130. Yang B, Lin L, Bazinet RP, et al. Clinical efficacy and biological regulations of ω-3 PUFA-derived endocannabinoids in major depressive disorder. Psychother Psychosom. 2019;88(4):215–224. doi:10.1159/000501158

131. Coryell WH. Essential fatty acids for major depression. NLM identifier: NCT00256412; 2014 Available from: https://clinicaltrials.gov/ct2/show/NCT00256412?cond=major+depression&intr=essential+fatty+acids&draw=2&rank=1. Accessed July 22, 2014.

132. Raison C, Rutherford RE, Woolwine B, et al. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation. Brain Behav Immun. 2012;26(suppl 1):S49. doi:10.1016/j.bbi.2012.07.200.W

133. Andrade C. Mean difference, Standardized Mean Difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry. 2020;81(5):20f13681. doi:10.4088/JCP.20f13681

134. Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:863. doi:10.3389/fpsyg.2013.00863

135. Alba AC, Alexander PE, Changa J, MacIsaac J, DeFry S, Guyatt GH. High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes. J Clin Epidemiol. 2016;70:129–135. doi:10.1016/j.jclinepi.2015.09.005

136. Russo MW. How to review a meta-analysis. Gastroenterol Hepatol. 2007;3(8):637–642.

137. Andrade C. Anti-inflammatory treatments for depression: perspectives on how to read a meta-analysis critically. J Clin Psychiatry. 2019;80(3):19f12907. doi:10.4088/JCP.19f12907

138. Silverman MN, Sternberg E. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci. 2012;1261:55–63. doi:10.1111/j.1749-6632.2012.06633.x

139. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. doi:10.1016/S0140-6736(17)32802-7

140. Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601–609. doi:10.1016/S2215-0366(19)30217-2

141. Guo X, McCutcheon RA, Pillinger T, et al. The magnitude and heterogeneity of antidepressant response in depression: a meta-analysis of over 45,000 patients. J Affect Disord. 2020;276:991–1000. doi:10.1016/j.jad.2020.07.102

142. Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: towards precision medicine. Nat Rev Drug Discov. 2022;21:224–244. doi:10.1038/s41573-021-00368-1

143. Sorgdrager FJH, Naudé PJW, Kema IP, Nollen EA, De Deyn PP. Tryptophan metabolism in inflammaging: from biomarker to therapeutic target. Front Immunol. 2019;10:2565. doi:10.3389/fimmu.2019.02565

144. Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200. doi:10.1186/1741-7015-11-200

145. Medina-Rodriguez EM, Lowell JA, Worthen RJ, Syed SA, Beurel E. Involvement of innate and adaptive immune systems alterations in the pathophysiology and treatment of depression. Front Neurosci. 2018;12:547. doi:10.3389/fnins.2018.00547

146. Visentin A, Colombo R, Scotton E, et al. Targeting inflammatory-mitochondrial response in major depression: current evidence and further challenges. Oxid Med Cell Longev. 2020;2020:2972968. doi:10.1155/2020/2972968

#HololiveEN #Hololive #Vtubers

https://www.youtube.com/@NanashiMumei
Nanashi Mumei Ch. hololive-EN
Clip source: https://www.youtube.com/watch?v=rtyHVGSc91Y
Title: #memeMEI #drawMEI #ムメ絵
【MINECRAFT】Diamond Doko ft. Open VC

https://www.youtube.com/@KaelaKovalskia
Kaela Kovalskia Ch. hololive-ID
Clip source: https://www.youtube.com/watch?v=359M_p-uKTA
Title: #KaelaKovalskia #KaeLaugh #holoID
【Minecraft】hmmm.. hehe hehe ⛏️【Kaela Kovalskia / hololiveID】

@hololive – hololive ホロライブ – VTuber Group
Outro music source
Source: https://youtu.be/zkXvWvTX_BE?t=3637
Title
【#つながるホロライブDAY1】hololive 3rd fes. Link Your Wish【チラ見せ】【#つながるホロライブDAY1】
@oo oxygen CLEANSE

Art source by: @Fongban_illust

Falling Owl
❓
🦉#drawMEI #inKaela pic.twitter.com/LMdErHx324

— Fongban法巴🍻COMMS OPEN (@Fongban_) July 29, 2022

☆*:.｡.oo.｡.:*☆ ◕✿°˖✧◝♫•*¨*•.¸¸♪◜✧˖°☆*:.｡.oo.｡.:*☆

https://twitter.com/hololivetv – ホロライブプロダクション【公式】
@hololivetv

https://twitter.com/hololivepro_EN – hololive production (English)
@hololivepro_EN
https://twitter.com/hololive_En – hololive Official
@hololive_En
https://twitter.com/hololive_music – hololive music
@hololive_music

[Official Online Shop of Hololive]
https://shop.hololivepro.com/
https://hololive.booth.pm/
https://shop.geekjack.net/

[Holoschedule] (Check all members streaming schedules)
https://schedule.hololive.tv/

☆*:.｡.oo.｡.:*☆ ◕✿°˖✧◝♫•*¨*•.¸¸♪◜✧˖°☆*:.｡.oo.｡.:*☆

For the background BGM mostly use @hololiveEnglish
https://www.youtube.com/channel/UCotXwY6s8pWmuWd_snKYjhg
Visit: https://dova-s.jp/ Thank you

Please read the “License” and “Agreement at the website.

The Official youtube channel: @DOVASYNDROMEYouTubeOfficial
https://www.youtube.com/c/DOVASYNDROMEYouTubeOfficial

☆*:.｡.oo.｡.:*☆ ◕✿°˖✧◝♫•*¨*•.¸¸♪◜✧˖°☆*:.｡.oo.｡.:*☆

Hololive Official website for more Information :
https://www.hololive.tv/
https://en.hololive.tv/
https://cover-corp.com/

“Please read Derivative work guidelines”
https://www.hololive.tv/terms

( ˇ෴ˇ ) ☆*:.｡.oo.｡.:*☆ ◕✿°˖✧◝♫•*¨*•.¸¸♪◜✧˖°☆*:.｡.oo.｡.:*☆ (ᗒᗣᗕ)՞

Hello everyone I’m Yagoo Shadow (kage) and I make Hololive remixes and video clips. LMAO
Just please support the main channel of Hololive members at the description of each videos. Hololive is organic medicine.
Thank you.
+ﾟ*｡:ﾟ+凸(◕‿◕✿)+ﾟ*｡:ﾟ+

My twitter: https://twitter.com/clozt3 – @clozt3

#HololiveEnglish #HoloEn #HololiveEn #vtuber #vtuberen #virtualidol #clips #memes #shorts
​ #Hololive #HololiveEn #Anime #animegirls #vtuber

Jason Brown demonstrates his final section of his 2023 Free Program to “The Impossible Dream” by @JoshGroban, at the Toronto Cricket Skating & Curling Club in Toronto, Ontario.

Choreography by Rohene Ward.

Filmed November 2022 by Jordan Cowan of @OnIcePerspectives.

On Ice Perspectives is made possible by viewers like you. Become a supporter and help us continue to make and publish free online skating videos at http://oniceperspectives.com/support.

Contact: http://oniceperspectives.com/contact

More On Ice Perspective on the web:
Website – http://www.oniceperspectives.com
Instagram – ‘@oniceperspectives’ http://instagram.com/oniceperspectives
TikTok – ‘@oniceperspectives’ http://tiktok.com/@oniceperspectives
YouTube – http://youtube.com/oniceperspectives
Facebook – http://facebook.com/oniceperspectives
Twitter – ‘@iceperspectives’ http://twitter.com/iceperspectives
Twitch – http://twitch.tv/oniceperspectives
Patreon – http://patreon.com/oniceperspectives

#iceskating #figureskating #oniceperspectives #icedancing #icedance #iceskate #figureskate #jasonbrown #joshgroban #theimpossibledream #shorts

What would you tell your future self?
#OwnToday

___________________________________________________________________________________
Join FREELETICS now and start your journey towards your greatest version today.

▶ Start today: https://www.freeletics.com/en/training/coach/get/running/1/

Training & Nutrition
Custom Training Journeys
Digital AI coaching
Nutrition guidance
Inspiring motivational stories
And more to come …

Follow us on Social Media:
▶ YouTube: https://www.youtube.com/user/Freeletics
▶ Instagram: https://www.instagram.com/freeletics/
▶ Facebook: https://www.facebook.com/Freeletics/
▶ Shop: https://shop.freeletics.com/
▶ Blog: https://www.freeletics.com/en/blog/
▶ Twitter: https://twitter.com/Freeletics

A blue Adolf Hitler moustache had been daubed onto a portrait of the Duke of Caxias, a 19th century prime minister, on the second floor of Brazil’s presidential palace.

A multimillion dollar masterpiece by the modernist legend Emiliano Di Cavalcanti was stabbed seven times.

Not even the palace’s press rooms escaped the wrath of thousands of far-right insurrectionists when they stormed the building on Sunday afternoon, as well as the national congress and supreme court.

After smashing their way into Oscar Niemeyer’s breathtaking curved creation, extremists relieved themselves in the press room and defecated in the room for photographers next door.

“The whole place stank of urine and beer,” one palace employee said of the moment officials reentered the building after Sunday’s day of rage to discover scenes of inconceivable depredation.

The Guardian toured two of the three ransacked buildings in Brasília on Monday afternoon, 24 hours after the attack by hardcore followers of the former president Jair Bolsonaro.

The Planalto palace and the national congress are both architectural gems at the heart of Niemeyer and urban planner Lúcio Costa’s bold 1950s vision of a new, forward-looking Brazil.

Both now appear to have been hit by a natural disaster, their outer windows smashed to smithereens by rampaging Bolsonaristas desperate to overturn the result of October’s election, which their radical leader lost to his left-wing rival Luiz Inácio Lula da Silva.

At the senate museum, plaques still read: “Please do not touch the artwork.” But rioters ignored those as they swept into the exhibit room and began wrecking hundreds of years of Brazilian art and political history.

A knife had been taken to portraits of former senate presidents Renan Calheiros and José Sarney. A copy of the Brazilian constitution had been slammed through the top of a display case and was now framed by shards of broken glass.

Outside, the right-wing rebels had left artwork of their own; crudely scrawled graffiti demanding a pro-Bolsonaro military coup and an end to the communist threat they are convinced has taken hold of Brazil with Lula’s election win.

“Scumbags,” one cleaning lady fumed of the putschists as she and dozens of others swept congress’s glass-covered blue and lime green carpets and engineers checked for structural damage.

Nearby, the entrance to the offices of the senate’s current president, Rodrigo Pacheco, looked like a bank that had been targeted by ram-raiders. A Chinese X-ray machine lay on its side; chunks of glass covered the floor; internet cables dangled from the ceiling like vines; two shattered desktop computers lay on a table, their motherboards spilling out from inside.

At the presidential palace, there were similar scenes of gratuitous and often infantile destruction.

Cobblestones had been ripped up from the entrance, where just one week earlier hundreds of guests had celebrated Lula’s inauguration and what they had hoped would be a progressive new era of reconciliation and environmental protection after four years of division and hate.

Cleaners waded through the ornamental water features beneath the palace’s marble ramp using nets to fish out the detritus of the previous day’s chaos.

“Bottles, glass, [rubber] bullets,” one of the workers said of the objects being retrieved from the water mirror as the clean-up continued.

The rioters made it into the inner sanctum of what should be one of Brazil’s most secure addresses, leaving a bizarre trail of destruction and fury in their wake and many questions over how such a politically-sensitive building could have been left so exposed.

The mob failed to access the offices of president Lula but other rooms were looted and smashed. A felt-tip pen was used to scrawl curly lines along the ceiling of the corridor occupied by members of the Institutional Security Bureau, which is responsible for the president’s safety. Chairs were hurled from the broken windows and rioters tried to torch a sofa.

One of Lula’s closest aides, Celso Amorim, said his office and that of Brazil’s first lady, Rosângela Lula da Silva, had been vandalized, with the insurgents appearing to trash her workplace with particular relish.

Amorim, who is Brazil’s former defense minister, said he was struggling to fathom how security forces and intelligence agencies had failed to detect or stop the threat. “The resistance only came after the deed had been done – it’s as if it was allowed to happen,” he said.

Journalists were not allowed into the third sacked building, the supreme court, on Monday afternoon as federal police forensic officers picked their way through its wreckage in search of fingerprints, clues and perhaps even booby traps left by the Bolsonaristas. But the white graffiti on the court’s facade spoke to the bedlam that had unfolded inside. “I came, I won,” said one daubed slogan. Another read: “You lost, you prick.”

As the Guardian approached the building, a black-clad member of the bomb disposal unit asked reporters to retreat: the controlled explosion of what he called “a grenade” was being carried out just metres from its entrance.

Minutes later, an ear-splitting bang rang out across the Three Powers Plaza, which Costa and Niemeyer had intended as a symbol of political harmony between Brazil’s executive, judiciary and legislative branches.

“It’s heartbreaking,” said a military policeman who was guarding the court and said several of his colleagues had been injured during the pro-Bolsonaro rampage. “Let us hope that better days lie ahead.”